Quick Answer
Humacyte, Inc. reported Cash and Equivalents of $50.50 million for fiscal year 2025.
Humacyte, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $50.50M | +12.4% |
| 2024 | $44.94M | -44.1% |
| 2023 | $80.45M | -46.3% |
| 2022 | $149.77M | -31.1% |
| 2021 | $217.50M | +444.7% |
| 2020 | $39.93M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.49M | -5.3% | -48.8% |
| June 30, 2025 | $38.03M | -59.4% | -39.5% |
| March 31, 2025 | $62.85M | -45.6% | +39.9% |
| December 31, 2024 | $44.94M | -44.1% | +118.4% |
| September 30, 2024 | $20.57M | -79.4% | -78.0% |
| June 30, 2024 | $93.56M | -18.4% | -19.0% |
| March 31, 2024 | $115.50M | -10.9% | +43.6% |
| December 31, 2023 | $80.45M | -46.3% | -19.5% |
- Humacyte, Inc. showed an increase of +12.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Humacyte, Inc.’s cash and equivalents has grown by 26.5% (from $39.93 million to $50.50 million).
- The most recent figure is from Humacyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: